New hope for MS patients: drug access program opens for those with no alternatives
NCT ID NCT04540861
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides access to siponimod, a medication that helps control active secondary progressive multiple sclerosis (SPMS). It is for adult patients who have no satisfactory treatment options. Doctors can request the drug for eligible patients through a compassionate use process.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Simple chin and neck exercises put to the test for MS swallowing problems
- Could a daily walk shield the brain's wiring in aging MS patients?
- Brain boot camp: can a memory-training program sharpen thinking in multiple sclerosis?
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Brain training without drugs: can imagining movement ease MS pain?